# High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

> **NCT05895201** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Indiana University**

## Conditions studied

- Bone Marrow Transplant Complications
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia, Adult
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Bortezomib
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05895201
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-11
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI has left IU with no plan to initiate study at IU
- **Last updated:** 2024-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05895201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05895201, "High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05895201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*